A Lack of Premature Termination Codon Read-Through Efficacy of PTC124 (Ataluren) in a Diverse Array of Reporter Assays

PLoS Biology

Volumn 11, Issue 6, 2013, Pages

  McElroy, Stuart P ^a   Nomura, Toshifumi ^b   Torrie, Leah S ^a   Warbrick, Emma ^a   Gartner, Ulrike ^a   Wood, Gavin ^a   McLean, W H Irwin ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC G 418; ATALUREN; BETA GALACTOSIDASE; FIREFLY LUCIFERASE;

ARTICLE; BIOASSAY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; IN VITRO STUDY; NONSENSE MUTATION; REPORTER ASSAY; STOP CODON;

ANIMALS; BETA-GALACTOSIDASE; BIOLOGICAL ASSAY; CELL LINE; CODON, NONSENSE; COLLAGEN TYPE VII; GENES, REPORTER; GENTAMICINS; HUMANS; LUCIFERASES, FIREFLY; OXADIAZOLES; TRANSFECTION;

EID: 84879391161     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001593     Document Type: Article

References (24)

1. Nicholson P, Muhlemann O, (2010) Cutting the nonsense: the degradation of PTC-containing mRNAs. Biochem Soc Trans 38: 1615-1620.
2. Kellermayer R, (2006) Translational readthrough induction of pathogenic nonsense mutations. Eur J Med Gen 49: 445-450.
3. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87-91.
4. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, et al. (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci U S A 105: 2064-2069.
5. Wang B, Yang Z, Brisson BK, Feng H, Zhang Z, et al. (2010) Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J Appl Physiol 109: 901-905.
6. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, et al. (2008) Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372: 719-727.
7. Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, et al. (2010) Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J respiratory and critical care medicine 182: 1262-1272.
8. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, et al. (2011) Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 38: 59-69.
9. Auld DS, Thorne N, Maguire WF, Inglese J, (2009) Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci U S A 106: 3585-3590.
10. Auld DS, Lovell S, Thorne N, Lea WA, Maloney DJ, et al. (2010) Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc Natl Acad Sci U S A 107: 4878-4883.
11. Thorne N, Inglese J, Auld DS, (2010) Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. Chemistry & biology 17: 646-657.
12. Peltz SW, Welch EM, Jacobson A, Trotta CR, Naryshkin N, et al. (2009) Nonsense suppression activity of PTC124 (ataluren). Proc Natl Acad Sci U S A 106: E64 author reply E65.
13. Tan L, Narayan SB, Chen J, Meyers GD, Bennett MJ, (2011) PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. Journal of inherited metabolic disease 34: 443-447.
14. Mellerio JE, Dunnill MG, Allison W, Ashton GH, Christiano AM, et al. (1997) Recurrent mutations in the type VII collagen gene (COL7A1) in patients with recessive dystrophic epidermolysis bullosa. The Journal of investigative dermatology 109: 246-249.
15. van den Akker PC, Jonkman MF, Rengaw T, Bruckner-Tuderman L, Has C, et al. (2011) The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat 32: 1100-1107.
16. Bidou L, Hatin I, Perez N, Allamand V, Panthier JJ, et al. (2004) Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther 11: 619-627.
17. Manuvakhova M, Keeling K, Bedwell DM, (2000) Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6: 1044-1055.
18. Kopelowitz J, Hampe C, Goldman R, Reches M, Engelberg-Kulka H, (1992) Influence of codon context on UGA suppression and readthrough. J Molec Biol 225: 261-269.
19. Dranchak PK, Di Pietro E, Snowden A, Oesch N, Braverman NE, et al. (2011) Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J Cell Biochem 112: 1250-1258.
20. Harmer SC, Mohal JS, Kemp D, Tinker A, (2012) Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channel. Biochem J 443: 635-642.
21. Brumm H, Muhlhaus J, Bolze F, Scherag S, Hinney A, et al. (2012) Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through. Obesity 20: 1074-1081.
22. Koopmann TT, Verkerk AO, Bezzina CR, de Bakker JM, Wilde AA, (2012) The chemical compound PTC124 does not affect cellular electrophysiology of cardiac ventricular myocytes. Cardiovasc Drugs Ther 26: 41-45.
23. Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K, (2011) PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C. Human Gene Ther 22: 537-547.
24. Sarkar C, Zhang Z, Mukherjee AB, (2011) Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. Mol Gen Metabol 104: 338-345.